Patients with relapsed/refractory B-cell NHL and CLL were enrolled in this study.
The main inclusion criteria were: age ≥20 years; confirmed his- Informed consent was obtained from all patients prior to enrollment. The study protocol and all amendments were reviewed by ethics committees at each participating center. The study was conducted according to the protocol, Good Clinical Practice guidelines, applicable local regulations and the Declaration of Helsinki.
| Study design
Patients were enrolled from January 2015 to February 2016 in 4 dose cohorts of 160 mg QD, 320 mg QD, 480 mg QD and 300 mg BID (Cohorts 1-4). The study design was a 3 + 3 dose escalation scheme where patients were observed for a 28-day period to identify dose-limiting toxicities (DLT), which are defined as drug-related AEs that occurred in the first 28 days after the first dose. Further information on the definition of DLT is described in Data S1.
Tirabrutinib administration was continued until progressive disease, unacceptable AEs or consent withdrawal. PK was assessed on Day 1 and Day 28 in Cycle 1. Criteria for the discontinuation or interruption, resumption and dose modifications included AEs meeting DLT criteria, AEs not related to tirabrutinib, a patient's wish to discontinue, not meeting inclusion criteria and meeting exclusion criteria. The full criteria for discontinuation or interruption, resumption, and dose modification are described in Data S1.
| Assessments

| Safety
Adverse events were evaluated using the Common Terminology Criteria for Adverse Events (Ver. 4.0). Laboratory tests, vital signs and electrocardiograms were also assessed using conventional methods.
| Efficacy
The assessment of best clinical response was based on International Workshop Criteria for B-cell NHL patients, 8 WM patients 9 and CLL patients. 10 Drug efficacy evaluation was based on the following:
overall response rate (ORR), CR (CR unconfirmed or CR with incomplete blood count recovery), partial response rate (PR or very good PR), progression-free survival, overall survival, duration of response and event-free survival.
| Pharmacokinetics
Blood for the PK analysis was drawn on 
| Pharmacodynamics
Bruton's tyrosine kinase phosphorylation inhibition in peripheral blood mononuclear cells was assessed using western blotting analysis at Day 1 of Cycle 1, from a blood sample taken pre−dose and at 2 hours post-dose. Primary antibodies included anti-phosphorylated BTK (pBTK) (Abcam, Cambridge, MA, USA), anti-BTK (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-beta actin (Sigma-Aldrich). Additional details are provided in Data S1. PR with residual lymphocytosis) was calculated for the entire study population, and for each treatment cohort and histology.
| Biomarker analysis
| RE SULTS
| Patients and treatment
Overall, 17 patients with a median age of 70 years (range, 37-80)
were enrolled (N = Table 1 . The median duration of study drug administration was 161 days (range, 5-1037 days), and the median number of cycles administered was 7 (range, 1-38).
| Safety and tolerability
Tirabrutinib was generally well tolerated ( Table 2) F I G U R E 1 Maximum change in the orthogonal sum of the products of the greatest diameters of the target region (A) and the time to response and duration of response (B). +, censor; FAS, full analysis set
population, included anemia, constipation, diarrhea, nausea, malaise, arthralgia and insomnia (17.6% each). 
| Efficacy
The ORR for all patients was 76.5% (13/17 patients) (Table 3) , and the subgroup analysis showed that the ORR for non−GCB DLBCL was 75.0% (3/4 patients) ( Table 4) The rates and their 95% confidence intervals were calculated using the Clopper-Pearson method. DLBCL, diffuse large B-cell lymphoma; non−GCB DLBCL, non−germinal center B-cell-like diffuse large B-cell lymphoma.
F I G U R E 2 CXCL-10 percent change from baseline in all 13 responders (partial response or more) on C1D8 and C1D28. Bold squares represent the average value
| Pharmacokinetics
The plasma concentrations of tirabrutinib for all cohorts are shown in Figure 3A ,B. The PK parameters C max , T max , AUC 12 h , AUC 24 h , AUC inf and T 1/2 on C1D1 and C1D28 are shown in Table S1 .
| Pharmacodynamics
Treatment with tirabrutinib suppressed the expression level of pBTK in all 11 patients with confirmed pBTK expression at the basal level.
pBTK on C1D1 was rapidly eliminated in these 11 patients (data not shown). Expression was suppressed in the CLL patient in a timedependent manner. Complete suppression was observed in the other patients at 2 hours post-dose on Day 1 of Cycle 1 (Figure 4 ).
Basal expression of pBTK was below the detection limit in 6 of 17 patients.
| D ISCUSS I ON
This study evaluated the MTD, safety, efficacy, PK and PD of tirabrutinib monotherapy in 17 Japanese patients with relapsed or refractory B-cell NHL and CLL. Furthermore, we conducted the first biomarker analysis of tirabrutinib in humans. We found that tirabrutinib was well tolerated and demonstrated promising efficacy in a group of Japanese B-cell NHL and CLL patients. Tolerability up to 300 mg BID was confirmed, and the MTD was not reached.
Therefore, the recommended dosing schedule of tirabrutinib in Japanese patients with B-cell NHL and CLL is either 480 mg QD or 300 mg BID. However, it is still necessary to consider which dosage is recommended for each histological subtype.
No DLT was identified in Cohorts 1-3. A DLT (grade 3 pneumonitis) was observed in 1 WM patient in Cohort 4 (300 mg BID), but it resolved with supportive measures, and study treatment was resumed at a lower dose. Organized pneumonia was present before the patient entered the study. All AEs were manageable and resolved with temporary dose interruption or the administration of granulocyte colony-stimulating factor or other agents. There were no clinically significant AEs in this group of Japanese patients, and the safety profile and most common AEs (neutropenia and anemia)
were similar to those reported in the European phase I study.
7
A response was seen beginning at 160 mg QD. No correlation was found between response rate and dose, possibly because the dose was gradually increased from an initial dose at which an adequate response was observed in a previous phase I study and the number of enrolled patients was small. 7 Histological subtypes may have also influenced the response. In the current study, 1 CLL patient (160 mg QD) had a TP53 mutation but achieved PR, and treatment is currently ongoing, despite the poor prognosis with TP53 mutation reported for this type of case treated by conventional chemotherapy. [14] [15] [16] The efficacy of tirabrutinib against CLL with TP53 mutation may be comparable with that of ibrutinib.
For patients with CXCL-10 levels > 1000 pg/mL, it was difficult to evaluate the effect of the study drug on CXCL-10 levels because an increase in CXCL-10 levels to >1000 pg/mL can be related to other complications (autoimmune disease or infection). Therefore, we only evaluated the change in CXCL-10 levels in patients with CXCL-10 ≤ 1000 pg/mL at baseline. CXCL-10 levels in responders with CXCL-10 ≤ 1000 pg/mL at baseline tended to be higher on C1D28 vs C1D8. This suggests that the administration of tirabrutinib suppresses CXCL-10 production from tumor cells over a short period; therefore, a fast-acting antitumor effect rapidly lowers CXCL-10 levels, and B-cell functions (including regulatory B-cells) are inhibited for a long period, accelerating Th1 functions. 17 Pharmacokinetics analysis demonstrated that the area under the concentration-time curve and maximum serum concentration were increased in a dose-dependent manner. Treatment with tirabrutinib at doses of ≥160 mg QD fully suppressed the expression of pBTK in all patients with confirmed basal expression of pBTK. In addition, pBTK in peripheral mononuclear cells was suppressed at 160 mg QD, indicating tumor shrinkage. However, although suppression of phosphorylation was seen in most patients, there were some non− responders. Therefore, further investigation is needed to validate pBTK as a biomarker.
In conclusion, in Japanese patients with B-cell NHL and CLL, tirabrutinib was well tolerated and showed promising efficacy with an acceptable PK profile for future development. Overall responses (≥PR) were observed in 76.5% of patients, including 4 DLBCL patients with no CD79A/B or MYD88 mutations, and 1 CLL patient with a TP53 mutation, providing promising data for future developments.
Based on the results of this phase I study, phase II studies of tirabrutinib monotherapy have already been initiated in Japanese patients with specific subtypes of B-cell NHL. In addition, large-scale clinical trials of tirabrutinib are required to elucidate the differences between tirabrutinib and other BTK inhibitors, such as ibrutinib and acalabrutinib.
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